Clinical trials: Patients Take Medicine
Heart Diseases
A Partnership to Translate an Evidence-based Intervention (Take Heart) for Vulnerable Older Adults With Heart Disease
To evaluate the effectiveness of Take Heart, a behavioral/educational program for adults age 50+ with heart disease, or with at least two risk factors for heart disease, that helps them to better manage their health condition(s).
- Trial name
- NCT02950818
- Testing
- Take Heart
- Where
- United States
- Volunteers
- 453 people
- Sponsor
- University of Michigan
Kidney Transplantation, Medication Adherence
Intervention to Improve Adherence in Teen Kidney Transplant
The broad aim of the proposed study is to improve medication adherence in adolescent kidney transplant recipients. The investigators hypothesize that a multi-component intervention will improve medication adherence in the…
- Trial name
- TAKE-IT (NCT01356277)
- Testing
- Action-focused problem-solving, Electronic pillbox monitoring, dose reminders, and feedback
- Where
- 8 sites in United States, Canada
- Volunteers
- 170 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Depressive Disorder, Major
A Study to Test Different Doses of BI 1569912 in People With Depression Who Take Anti-depressive Medicine
This study is open to adults between 18 and 65 with a type of depression (major depressive disorder) for whom previous treatments for depression did not work.
- Trial name
- NCT06280235
- Testing
- BI 1569912
- Where
- 52 sites in United States, Belgium and 5 more
- Volunteers
- 243 people
- Sponsor
- Boehringer Ingelheim
Diabetes Mellitus, Type 2
A Study Based on Data From German Registries That Looks at Characteristics of People Who Take the Medicine Empagliflozin for Type 2 Diabetes
Description of the real-life treatment of adult patients with type-2 diabetes mellitus (T2DM) receiving Empagliflozin, comparing the characteristics of patients starting Empagliflozin in three time intervals
- Trial name
- EDCOS (NCT04098575)
- Testing
- Empagliflozin
- Where
- Germany
- Volunteers
- 9,571 people
- Sponsor
- Boehringer Ingelheim
Depressive Disorder, Major
A Study to Test How Well Different Doses of BI 1569912 Are Tolerated and How Well They Work in People With Depression Who Take Anti-depressive Medication
This study is open to adults between 18 and 65 years of age who have depression (major depressive disorder). People with a current depressive episode lasting between 2 months and one and a half years can join the study.
- Trial name
- NCT04937829
- Testing
- 5 mg BI 1569912, 20 mg BI 1569912
- Where
- 10 sites in United States
- Volunteers
- 59 people
- Sponsor
- Boehringer Ingelheim